JNJ4796
JNJ4796 is an oral active fusion inhibitor of influenza virus, neutralizing influenza A group 1 viruses by inhibiting hemagglutinin (HA) -mediated fusion. JNJ4796 mimics the functionality of the broadly neutralizing antibodies (bnAbs) [1].
Product Specifications
CAS Number
2241664-16-2
UNSPSC
12352005
Target
Influenza Virus
Type
Reference compound
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/JNJ4796.html
Purity
99.94
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CC(NC1=CC=C(OC(C2=CC(C(N3CCN([C@@H](C4=NN(C)N=N4)C5=CC=CC=C5)CC3)=O)=NC=C2)=N6)C6=C1)=O
Molecular Formula
C28H27N9O3
Molecular Weight
537.57
References & Citations
[1]van Dongen MJP, et al. A small-molecule fusion inhibitor of influenza virus is orally active in mice. Science. 2019 Mar 8;363 (6431) .
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Human Cgmp-Dependent Protein Kinase 2 (PRKG2) Protein
Human Cgmp-Dependent Protein Kinase 2 (PRKG2) Protein
Human Cgmp-Dependent Protein Kinase 2 (PRKG2) Protein
Human Cgmp-Dependent Protein Kinase 2 (PRKG2) Protein
Human Cgmp-Dependent Protein Kinase 2 (PRKG2) Protein
![p16INK4A (CDKN2A) Mouse Monoclonal Antibody [Clone ID: OTI5H5]](https://cdn.genprice.uk/products/937/68dd18b9061270361e907cb9/imageurl/cf805237.webp)